The use of bioreactors as in vitro models in pharmaceutical research

Drug Discovery Today

Volumn 18, Issue 19-20, 2013, Pages 922-935

  Ginai, Maaria ^a   Elsby, Robert ^b   Hewitt, Christopher J ^a   Surry, Dominic ^b   Fenner, Katherine ^b   Coopman, Karen ^a  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AMINO ACID; BICARBONATE; CELLULOSE; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DICLOFENAC; DIMETICONE; DRUG METABOLITE; GLUCOSE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HYDROXYDICLOFENAC; MORPHINE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NEW DRUG; ORGANIC ANION TRANSPORTER; POLYETHERSULFONE; POLYMER; POVIDONE; UNCLASSIFIED DRUG;

AMINO ACID TRANSPORT; ARTIFICIAL KIDNEY; ARTIFICIAL LIVER; BIOREACTOR; BLOOD BRAIN BARRIER; CELL CULTURE; CELL MEMBRANE; CELL SPECIFICITY; CENTRAL NERVOUS SYSTEM; CHRONIC KIDNEY DISEASE; CONTINUOUS HEMOFILTRATION; CYTOTOXICITY TEST; DEVICES; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; DRUG TRANSPORT; ELECTRIC RESISTANCE; EMBRYONIC STEM CELL; ENDOTHELIUM CELL; ENZYME ACTIVITY; GLUCOSE TRANSPORT; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; KIDNEY TUBULE CELL; LIVER CELL; MEDICAL DEVICE; MICROFLUIDICS; MICROVASCULATURE; MODEL; MODULAR EXTRACORPOREAL LIVER SUPPORT SYSTEM; NONHUMAN; REVIEW; TISSUE ENGINEERING; TOXICITY TESTING;

ANIMALS; BIOARTIFICIAL ORGANS; BIOMEDICAL RESEARCH; BIOREACTORS; HUMANS; MODELS, BIOLOGICAL; TECHNOLOGY, PHARMACEUTICAL;

EID: 84884595531     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.05.016     Document Type: Review

References (86)

1. D.W. Light Drug R&D costs questioned Genet. Eng. Biotechnol. News 31 2011 6 7
2. F. Scherer R&D Costs and Productivity in Biopharmaceuticals 2011 F Kennedy School of Government, Harvard University
3. A. Astashkina A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity Pharmacol. Ther. 134 2012 82 106
4. P. Ballard The right compound in the right assay at the right time: an integrated discovery DMPK strategy Drug Metab. Rev. 44 2012 224 252
5. Barberis, A. (2002). Cell-based high-throughput screens for drug discovery. Eur. Biopharm. Rev. Winter, 93-96
6. J.C. Gerlach Bioartificial liver systems: why, what, whither? Regen. Med. 3 2008 575 595
7. R. Fahrig Use of primary rat and human hepatocyte sandwich cultures for activation of indirect carcinogens: monitoring of DNA strand breaks and gene mutations in co-cultured cells Toxicol. In Vitro 12 1998 431 444 (Pubitemid 28352755)
8. H. Cai Assessment of the renal toxicity of novel anti-inflammatory compounds using cynomolgus monkey and human kidney cells Toxicology 258 2009 56 63
9. S.N. Bhatia Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells FASEB J. 13 1999 1883 1900 (Pubitemid 29517619)
10. B. Swift Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity Drug Metab. Rev. 42 2010 446 471
11. K. Hatherell Development of a three-dimensional, all-human in vitro model of the blood-brain barrier using mono-, co-, and tri-cultivation Transwell models J. Neurosci. Methods 199 2011 223 229
12. M.I. Hermanns Lung epithelial cell lines in coculture with human pulmonary microvascular endothelial cells: development of an alveolo-capillary barrier in vitro Lab. Invest. 84 2004 736 752 (Pubitemid 38715474)
13. Sceats, E. (2010). In vitro tissue models: working in the third dimension. Innovat. Pharm. Technol. 28-32
14. N.T. Elliott, and F. Yuan A review of three-dimensional in vitro tissue models for drug discovery and transport studies J. Pharm. Sci. 100 2011 59 74
15. R. Pörtner Bioreactor design for tissue engineering J. Biosci. Bioeng. 100 2005 235 245 (Pubitemid 41755286)
16. M. Radisic. Mathematical model of oxygen distribution in engineered cardiac tissue with parallel channel array perfused with culture medium containing oxygen carriers Am. J. Physiol. Heart Circ. Physiol. 288 2005 H1278 H1289
17. D. Wendt Bioreactors in tissue engineering: scientific challenges and clinical perspectives Adv. Biochem. Eng. Biotechnol. 112 2012 1 27
18. J.A. Bilello Effect of 2′,3′-didehydro-3′- deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies Antimicrob. Agents Chemother. 38 1994 1386 1391 (Pubitemid 24170724)
19. S.B.M. Usuludin Co-culture of stromal and erythroleukemia cells in a perfused hollow fiber bioreactor system as an in vitro bone marrow model for myeloid leukemia Biotechnol. Bioeng. 109 2012 1248 1258
20. E. Schmelzer Effect of human patient plasma ex vivo treatment on gene expression and progenitor cell activation of primary human liver cells in multi-compartment 3D perfusion bioreactors for extra-corporeal liver support Biotechnol. Bioeng. 103 2009 817 827
21. K. Zeilinger Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies Tissue Eng. C 17 2011 549 556
22. J-K. Park, and D-H. Lee Bioartificial liver systems: current status and future perspective J. Biosci. Bioeng. 99 2005 311 319 (Pubitemid 40740580)
23. J.W. Allen Advances in bioartificial liver devices Hepatology 34 2001 447 455 (Pubitemid 32786634)
24. K.N. Matsumura Hybrid bioartificial liver in hepatic failure: preliminary clinical report Surgery 101 1987 99 103 (Pubitemid 17218385)
25. L. De Bartolo A novel full-scale flat membrane bioreactor utilizing porcine hepatocytes: cell viability and tissue-specific functions Biotechnol. Prog. 16 2000 102 108 (Pubitemid 30097658)
26. K. Naruse Development of a new bioartificial liver module filled with porcine hepatocytes immobilized on non-woven fabric Int. J. Artif. Organs 19 1996 347 352
27. N.L. Sussman Extracorporeal liver support. Application to fulminant hepatic failure J. Clin. Gastroenterol. 18 1994 320 324 (Pubitemid 24160730)
28. M. Ni Characterization of membrane materials and membrane coatings for bioreactor units of bioartificial kidneys Biomaterials 32 2011 1465 1476
29. M.J. Gómez-Lechón Hepatocytes: the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo Chem. Biol. Interact. 168 2007 30 50 (Pubitemid 46659918)
30. M.J. Gómez-Lechón Human hepatocytes as a tool for studying toxicity and drug metabolism Curr. Drug Metab. 4 2003 292 312 (Pubitemid 36958330)
31. R. Baudoin Behavior of HepG2/C3A cell cultures in a microfluidic bioreactor Biochem. Eng. J. 53 2011 172 181
32. L.C. Snouber Metabolomics-on-a-chip of hepatotoxicity induced by anticancer drug flutamide and its active metabolite hydroxyflutamide using HepG2/C3a microfluidic biochips Toxicol. Sci. 132 2013 8 20
33. S. Wilkening Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties Drug Metab. Dispos. 31 2003 1035 1042 (Pubitemid 36975674)
34. M. Darnell In vitro evaluation of major in vivo drug metabolic pathways using primary human hepatocytes and HepaRG cells in suspension and a dynamic three-dimensional bioreactor system J. Pharmacol. Exp. Ther. 343 2012 134 144
35. M. Ulvestad Evaluation of organic anion-transporting polypeptide 1B1 and CYP3A4 activities in primary human hepatocytes and HepaRG cells cultured in a dynamic three-dimensional bioreactor system J. Pharmacol. Exp. Ther. 343 2012 145 156
36. M. Darnell Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor Drug Metab. Dispos. 39 2011 1131 1138
37. J.W. Allen, and S.N. Bhatia Improving the next generation of bioartificial liver devices Semin. Cell. Dev. Biol. 13 2002 447 454 (Pubitemid 36027150)
38. J.F. Patzer II Novel bioartificial liver support system: preclinical evaluation Ann. N. Y. Acad. Sci. 875 1999 340 352 (Pubitemid 29349084)
39. P.G. Gregory In vitro characterization of porcine hepatocyte function Cell Transplant. 9 2000 1 10 (Pubitemid 30438899)
40. M.T. Donato Characterization of drug metabolizing activities in pig hepatocytes for use in bioartificial liver devices: comparison with other hepatic cellular models J. Hepatol. 31 1999 542 549 (Pubitemid 29408740)
41. S. Naik. Isolation and culture of porcine hepatocytes for artificial liver support Cell Transplant. 5 1996 107 115
42. M. Vinken. Primary hepatocyte cultures as in vitro tools for toxicity testing: quo vadis? Toxicol. In Vitro 26 2012 541 544
43. A. Bader Tacrolimus (FK 506) biotransformation in primary rat hepatocytes depends on extracellular matrix geometry Naunyn Schmiedebergs Arch. Pharmacol. 353 1996 461 473
44. C. Selden, and H. Hodgson Cellular therapies for liver replacement Transpl. Immunol. 12 2004 273 288 (Pubitemid 38639723)
45. G.D. Block Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF alpha in a chemically defined (HGM) medium J. Cell Biol. 132 1996 1133 1149 (Pubitemid 26105500)
46. I. Jasmund Cultivation of primary porcine hepatocytes in an OXY-HFB for use as a bioartificial liver device Biotechnol. Progr. 18 2002 839 846 (Pubitemid 34853396)
47. M.P. Van de Kerkhove Clinical application of bioartificial liver support systems Ann. Surg. 240 2004 216 230 (Pubitemid 38963011)
48. Y-T. Ding, and X-L. Shi Bioartificial liver devices: perspectives on the state of the art Front. Med. 5 2011 15 19
49. G.V. Mazariegos First clinical use of a novel bioartificial liver support system (BLSS) Am. J. Transplant. 2 2002 260 266 (Pubitemid 36330244)
50. I.M. Sauer Concept for modular extracorporeal liver support for the treatment of acute hepatic failure Metab. Brain Dis. 17 2002 477 484 (Pubitemid 36204776)
51. M. Ulvestad OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture Biochem. Pharmacol. 82 2011 1219 1226
52. R. Elsby Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1 Clin. Pharmacol. Ther. 92 2012 584 598
53. Y.Y. Lau effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers Clin. Pharmacol. Ther. 81 2007 194 204 (Pubitemid 46174816)
54. N.J. Abbott Astrocyte-endothelial interactions at the blood-brain barrier Nat. Rev. Neurosci. 7 2006 41 53 (Pubitemid 41828930)
55. J.D. Huber Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier Trends Neurosci. 24 2001 719 725 (Pubitemid 33097539)
56. L. Cucullo Drug delivery and in vitro models of the blood-brain barrier Curr. Opin. Drug Discov. Dev. 8 2005 89 99 (Pubitemid 40116334)
57. S. Hori Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s) J. Neurochem. 90 2004 526 536 (Pubitemid 38989383)
58. L. Cucullo A new dynamic in vitro model for the multidimensional study of astrocyte-endothelial cell interactions at the blood-brain barrier Brain Res. 951 2002 243 254 (Pubitemid 35248021)
59. K.A. Stanness Morphological and functional characterization of an in vitro blood-brain barrier model Brain Res. 771 1997 329 342 (Pubitemid 27492111)
60. W. Neuhaus A novel flow based hollow-fiber blood-brain barrier in vitro model with immortalised cell line PBMEC/C1-2 J. Biotechnol. 125 2006 127 141 (Pubitemid 44066610)
61. O. Lacombe In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery Mol. Pharm. 8 2011 651 663
62. Taylor, L. (2012) England's '£1.4B price tag for kidney disease'. Pharma Times Online 9 August
63. H.D. Humes, and M.S. Szczypka Advances in cell therapy for renal failure Transpl. Immunol. 12 2004 219 227 (Pubitemid 38639718)
64. H.D. Humes Tissue engineering of a bioartificial renal tubule assist device: In vitro transport and metabolic characteristics Kidney Int. 55 1999 2502 2514 (Pubitemid 29256506)
65. A. Saito Present status and perspective of the development of a bioartificial kidney for chronic renal failure patients Ther. Apher. Dial. 10 2006 342 347 (Pubitemid 44154764)
66. H.D. Humes Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure Kidney Int. 66 2004 1578 1588 (Pubitemid 39298393)
67. Z.Y. Oo The performance of primary human renal cells in hollow fiber bioreactors for bioartificial kidneys Biomaterials 32 2011 8806 8815
68. G.M. Chertow, and S.S. Waikar Toward the promise of renal replacement therapy J. Am. Soc. Nephrol. 19 2008 839 840
69. H. Zhang The impact of extracellular matrix coatings on the performance of human renal cells applied in bioartificial kidneys Biomaterials 30 2009 2899 2911
70. R. Masereeuw, and F.G.M. Russel Therapeutic implications of renal anionic drug transporters Pharmacol. Ther. 126 2010 200 216
71. L.H. Lash Membrane transport function in primary cultures of human proximal tubular cells Toxicology 228 2006 200 218 (Pubitemid 44708447)
72. A. Verhulst Human proximal tubular epithelium actively secretes but does not retain rosuvastatin Mol. Pharmacol. 74 2008 1084 1091
73. G. Pietig Properties and regulation of organic cation transport in freshly isolated human proximal tubules J. Biol. Chem. 276 2001 33741 33746
74. L. Zhang Role of organic cation transporters in drug absorption and elimination Ann. Rev. Pharmacol. Toxicol. 38 1998 431 460 (Pubitemid 28231502)
75. E.M. Leslie Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense Toxicol. Appl. Pharmacol. 204 2005 216 237 (Pubitemid 40552845)
76. A. Enomoto Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors J. Pharmacol. Exp. Ther. 301 2002 797 802 (Pubitemid 34595067)
77. L.H. Lash Drug metabolism enzyme expression and activity in primary cultures of human proximal tubular cells Toxicology 244 2008 56 65 (Pubitemid 350299082)
78. L.C. Racusen Cell lines with extended in vitro growth potential from human renal proximal tubule: characterization, response to inducers, and comparison with established cell lines J. Lab. Clin. Med. 129 1997 318 329 (Pubitemid 27169434)
79. G. Szakács The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox) Drug Discov. Today 13 2008 379 393
80. H.D. Humes The bioartificial renal tubule assist device to enhance CRRT in acute renal failure Am. J. Kidney Dis. 30 1997 S28 S31
81. K.S. Dolt 14-P007 differentiation of human embryonic stem cells towards renal progenitors Mech. Dev. 126 2009 2
82. C.A. Batchelder Renal ontogeny in the rhesus monkey (Macaca mulatta) and directed differentiation of human embryonic stem cells towards kidney precursors Differentiation 78 2009 45 56
83. H.D. Humes Metabolic replacement of kidney function in uremic animals with a bioartificial kidney containing human cells Am. J. Kidney Dis. 39 2002 1078 1087 (Pubitemid 34454228)
84. Y. Sato Evaluation of proliferation and functional differentiation of LLC-PK1 cells on porous polymer membranes for the development of a bioartificial renal tubule device Tissue Eng. 11 2005 1506 1515 (Pubitemid 41636436)
85. G.I. Nedredal Significant contribution of liver nonparenchymal cells to metabolism of ammonia and lactate and cocultivation augments the functions of a bioartificial liver Am. J. Physiol. 293 2007 G75 G83
86. Y. Duan Shear-induced reorganization of renal proximal tubule cell actin cytoskeleton and apical junctional complexes Proc. Natl. Acad. Sci. U.S.A. 105 2008 11418 11423